Detailed interpretation of the key contents of the official instruction manual of Tenofovir Alafenamide Fumarate Tablets (Vemlidy)

1. Drug Overview and Mechanism of Action

Tenofovir alafenamide fumarate tablets (Vemlidy, trade name Vemlidy) is an oral antiviral drug mainly used to treat chronic hepatitis B (CHB). Its main active ingredient is Tenofovir alafenamide (TAF), which is a nucleotide reverse transcriptase inhibitor (NRTI). The drug is rapidly converted into tenofovir (Tenofovir, TFV) in the body and is further phosphorylated into active substances after entering hepatocytes. TFV-DP can effectively inhibit hepatitis B virus (HBV) DNA polymerase activity, block virus replication, thereby reducing HBV DNA levels in the blood, improving liver function and delaying disease progression.

Compared with traditional tenofovir disoproxil disoproxil (TDF), tenofovir alafenamide has higher accumulation in liver cells and lower plasma exposure. It can reduce the risk of nephrotoxicity and bone mass loss and improve the safety of long-term medication. It is one of the preferred drugs for hepatitis B patients.

2. Indications and drug users

Tenofovir alafenamide fumarate tablets are mainly suitable for:

Adult patients with chronic hepatitis B, including HBV surface antigen (HBsAg) positive, serum HBV DNA positive and patients with abnormal liver function;

For adult patients with liver fibrosis or cirrhosis, long-term suppression of viral replication can reduce the risk of liver disease progression;

Provides a safe alternative for patients with TDF intolerance or impaired renal function.

Clinical studies have shown that long-term use of tenofovir alafenamide fumarate can effectively inhibit HBV replication, improve ALT levels, and delay the progression of liver fibrosis. It is also safer than TDF in terms of renal function and bone density.

3. Usage, dosage and precautions

The standard adult dose of tenofovir alafenamide fumarate tablets is 25 mg, taken orally once a day. Can be taken with food or on an empty stomach. For patients with abnormal renal function, dose adjustment should be based on glomerular filtration rate (eGFR).

The following matters need to be paid attention to during medication:

1. Renal function monitoring: Serum creatinine, urine protein and renal tubular function indicators should be checked regularly for long-term use;

2.Bone density monitoring: Especially the elderly or patients with low bone mass in the past should pay attention to changes in bone density;

3.Drug interactions: TAFviaP-gpandBCRPTransporter metabolism, combined with potentP-gp inhibitors or inducers may affect drug exposure, so combined drugs should be used with caution;

4. Attention when discontinuing medication: Unplanned discontinuation may cause viral rebound and worsening of liver function, and should be gradually adjusted under the guidance of a doctor.

4. Efficacy and safety analysis

Clinical trials have shown that tenofovir alafenamide fumarate tablets have good efficacy in HBV DNA inhibition rate, ALT normalization rate and HBeAg seroconversion rate. Compared with TDF, TAF significantly improves nephrotoxicity and bone density loss, making long-term maintenance treatment safer. Common adverse reactions include headache, nausea, diarrhea, fatigue, etc., most of which are mild to moderate and tolerable.

Special groups such as Pregnant women, lactating women or pediatric patients still need to use it with caution according to the official instructions and clinical guidelines, and weigh the risks and benefits. Overall, tenofovir alafenamide fumarate tablets have both efficacy and safety in the long-term management of chronic hepatitis B and are an important choice for modern anti-HBV treatment.

5. Clinical application suggestions

1.Standardized long-term medication: Patients with chronic hepatitis B need to take medication regularly for a long time under the guidance of a doctor to avoid stopping the medication on their own, which may lead to virus rebound;

2.Individualized monitoring: regularly assess liver function, HBV DNA, kidney function and bone density, and adjust treatment plans based on test results;

3.Combined lifestyle intervention: abstaining from alcohol, eating healthily, and maintaining moderate exercise can help improve liver health and drug efficacy;

4. Pay attention to special groups: renal insufficiency, elderly patients and patients with comorbid diseases should be used with caution, and the dose should be adjusted or combined with other antiviral drugs if necessary.

Taken together, tenofovir alafenamide fumarate tablets provide a safe and effective long-term management solution for chronic hepatitis B patients by precisely inhibitingHBV replication, improving liver function, and reducing the risk of long-term medication.

Reference link:https://www.drugs.com

xa0